 Ezetimibe is a drug which inhibits the absorption of both dietary and biliary cholesterol in the small intestine. Ezetimibe has been approved for use in humans to lower serum cholesterol. Moreover, ezetimibe has been shown to ameliorate hepatic steatosis and cholesterol gallstone formation in animal models. Previous data from our lab have documented that ezetimibe lowers serum cholesterol, prevents biliary crystals and ameliorates cholecystosteatosis in lean mice fed a high fat diet. However, the influence of ezetimibe on gallbladder motility, absorption and accumulation of toxic fats, metabolites, cytokines and chemokines, cholecystosteatosis, have not been studied in humans. Therefore, the aims of this study are 1 to determine if ezetimibe normalizes resting and residual volume in patients with chronic acalculous cholecystitis, 2 to determine if ezetimibe normalizes gallbladder ion flux in patients with chronic acalculous cholecystitis and 3 to determine if ezetimibe normalizes gallbladder absorptionsecretion modulators as well as gallbladder fat, cytokines and chemkines. 